Chest
Original ResearchCOPDDeterminants of Underdiagnosis of COPD in National and International Surveys
Section snippets
Results
Among 30,874 participants aged 56 ± 11.3 years from 44 sites worldwide, 55.8% were women, and 22.9% were current smokers. More detailed information on demographics, smoking status, respiratory symptoms, and postbronchodilator lung function is presented in TABLE 2, TABLE 3.
Only 26.4% of all participants reported a previous lung function test ever and 5.0% a diagnosis of COPD, whereas 9.7% had a postbronchodilator FEV1/FVC < LLN. Population prevalence of COPD ranged from 3.6% in Barranquilla,
Discussion
The results indicate that COPD underdiagnosis is frequent but varied across sites and age-groups. However, this underdiagnosis is not related with COPD prevalence. Although the range of COPD prevalence by site varies fivefold (5.27 times), its underdiagnosis only varies twofold (1.97). Worldwide determinants of COPD underdiagnosis are male sex (except in Spain), younger age, never and current smoking, lower level of education, absence of reported symptoms, lack of previous spirometry, and
Recommendations and Conclusions
More research on strategies to reduce the overwhelming phenomenon of COPD underdiagnosis is needed. COPD underdiagnosis has remained high in many countries, even after years of multiple interventions such as population spirometry and case finding. Apart from primary care as the central venue to screen for COPD, other options might be considered, such as community pharmacies30 or actively searching for COPD associated with the presence of comorbid disease.31,32 Lessons of success in other
Acknowledgments
Author contributions: B. L. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects. B. L., J. B. S., M. S., and B. K. contributed to the study conception and design, data analysis and interpretation, and final approval of the manuscript; B. L. and J. B. S. contributed to the drafting of the manuscript; and L. E. V., L. G., P. B., M. M., F. G.-R., K. A., J. A., A.
References (35)
- et al.
Interpreting COPD prevalence estimates: what is the true burden of disease?
Chest
(2003) - et al.
Screening for and early detection of chronic obstructive pulmonary disease
Lancet
(2009) - et al.
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
Lancet
(1997) - et al.
COPD surveillance—United States, 1999-2011
Chest
(2013) - et al.
The EPI-SCAN survey to assess the prevalence of chronic obstructive pulmonary disease in Spanish 40-to-80-year-olds: protocol summary [in Spanish]
Arch Bronconeumol
(2009) - et al.
Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study)
Chest
(2008) - et al.
International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study
Lancet
(2007) - et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study
Lancet
(2005) - et al.
Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care [in Spanish]
Arch Bronconeumol
(2006) - et al.
Airflow obstruction in never smokers in five Latin American cities: the PLATINO study
Arch Med Res
(2012)
COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study
Respir Med
Chronic bronchitis and chronic obstructive pulmonary disease. The Finnish Action Programme, interim report
Respir Med
Global burden of COPD: systematic review and meta-analysis
Eur Respir J.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Am J Respir Crit Care Med
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet. 2013;381(9867):628]
Lancet
Measuring the global burden of disease
N Engl J Med
The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design
COPD
Cited by (293)
Underdiagnosis and misclassification of COPD in Sweden – A Nordic Epilung study
2023, Respiratory MedicineOccupational Contributions to Respiratory Health Disparities
2023, Clinics in Chest MedicineCOPD generates substantial cost for health systems
2023, The Lancet Global HealthImproving the diagnosis of chronic obstructive pulmonary disease starts with appropriate medical education
2023, Respiratory InvestigationTrends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017
2023, Archivos de Bronconeumologia
FUNDING/SUPPORT: The initial Burden of Obstructive Lung Disease (BOLD) program was funded in part by unrestricted educational grants to the coordinating center in Portland, Oregon, from Aventis, AstraZeneca, Boehringer Ingelheim GmbH, Chiesi Farmaceutici SpA, GlaxoSmithKline plc, Merck Sharp & Dohme Corp, Novartis AG, Pfizer Inc, Schering-Plough, Sepracor Inc, and the University of Kentucky The BOLD study is currently funded by a grant from The Wellcome Trust [085790/Z/08/Z], which supports the London, England, coordinating center. The Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) was funded by Boehringer Ingelheim GmbH. The Epidemiologic Study of COPD in Spain (EPI-SCAN) study was funded by an unrestricted grant from GlaxoSmithKline Spain. The Prevalence Study of COPD in Colombia (PREPOCOL) was sponsored by an educational contribution from the Colombian offices of Boehringer Ingelheim GmbH and Pfizer Inc (Bogotá, Colombia). Support for the present work was provided by European Respiratory Society Fellowship STRTF 326-2011.
originally published Online First May 7, 2015